CTCL

AcronymDefinition
CTCLCutaneous T Cell Lymphoma
CTCLColleges That Change Lives (college search resource; Westminster, MD)
CTCLCareless Talk Costs Lives (magazine)
CTCLCentral Texas Cricket League (est. 2002)
CTCLCiticorp Trustee Company Limited (London, England, UK)
CTCLChina Telecom Corporation Ltd.
CTCLComputer to Computer Link (investing)
References in periodicals archive ?
It is estimated, based upon review of historic published studies and reports and an interpolation of data on the incidence of CTCL that it affects over 20,000 individuals in the US, with approximately 2,800 new cases seen annually.
The Official Receiver s investigation uncovered that between 2011 and 2012 CTCL made sales totalling Au1.
The emergence of systemically administered HDACi inhibitors has proven to be a significant advance in the treatment of CTCL, particularly for patients with more advanced disease.
Completion of patient enrollment in this landmark study is a major milestone in our efforts to advance Clearazide through regulatory approval and to help patients with CTCL.
The study enrolled a total of 144 patients with CTCL whose malignant cells expressed the CD25 component of the IL-2 receptor.
There is a greater frequency among men than women and CTCL is more common after the age of 50.
Food and Drug Administration for the treatment of cutaneous manifestations in patients with CTCL who have progressive, persistent or recurrent disease on or following two systemic therapies.
Evidence of Zolinza's safety and effectiveness was developed in two clinical trials with 107 CTCL patients who received Zolinza after their disease had recurred following other treatments.
Although rhIL-12 is not effective for solid tumors, "these early results suggest that it will be at home for CTCL and possibly Kaposi's sarcoma and other lymphomas," Dr.
The average survival time for peoplewith advanced CTCL is about 30 months.
Soligenix is currently working with leading CTCL centers, as well as with the National Organization for Rare Disorders (NORD) and the Cutaneous Lymphoma Foundation (CLF) to begin a 120 subject pivotal Phase 3 clinical trial with SGX301 in the second half of 2015.